Given that the course of periodontal disease is marked by a discontinuous pattern of disease activity and inactivity showing exacerbation and remission of tissue destruction, a critical challenge for clinicians is not so much diagnosing or detection of clinical features of the disease, but rather identification of patients who have an elevated risk for expressing active/progressing disease.
Since periodontitis is an evolving disease, the trajectory / progression of disease should be optimally tracked and monitored at regular frequencies to detect early signs of problems. Unfortunately, current guidelines and classifications rely exclusively on clinical and radiographic measurements to identify existing disease. While these records are a good reflection of a patient’s past history, they fail to provide information on the current status of active disease or identify individuals and sites at risk for future disease. This is because active disease involves tissue destructive processes (biologic phenotype) that precede and subsequently trigger the resulting clinical signs and symptoms (clinical phenotype). A host of salivary biomarkers for PD have been identified and multiple commercial assays are currently available for use in the clinic, but most lack specificity for tissue destruction and/or are not amenable to point-of-care (POC) real-time testing.
CellectGen’s mission is to develop user-friendly, saliva-based POC platform technologies to help dentists identify patients with high risk of emerging active disease lesions in less than 15 minutes.
The technology is based on integrated components consisting of:
- Saliva collection - Our proprietary saliva collection and filtration device,
- Lateral flow based test - Our next generation point-of-care testing technology allows for detection, and measurement of levels of specific biomarkers of bone and soft tissue destruction.
- Mobile application - Our mobile app quantifies results and guides treatment in real-time more accurately, more easily, and cost-effectively than current existing methods, thus permitting patients to save their natural teeth. The app will not only increase the accuracy of the test by quantifying the results and eliminating the dentist’s reliance on visual assessments, but also expand access to data and trends on each patient, digitally.
Our products represent the next generation solutions, designed to improve early detection and prevention of dental implant failure and gum disease in the 64.7 million individuals who suffer from various forms of the disease